Galmed Pharmaceuticals (GLMD) Cash & Current Investments (2013 - 2025)

Galmed Pharmaceuticals' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $4.1 million for Q4 2025.

• In Q4 2025, Cash & Current Investments fell 49.57% year-over-year to $4.1 million; the TTM figure through Dec 2025 stood at $4.1 million (down 49.57% YoY), while the FY2025 annual figure was $4.1 million, down 49.57% from the prior year.
• Cash & Current Investments was $4.1 million for Q4 2025 at Galmed Pharmaceuticals, up from $1.7 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $34.8 million in Q4 2021 to a low of -$2.2 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $5.5 million across 5 years, with a median of $3.7 million in 2021.
• The sharpest annual moves came in 2023 and 2025: Cash & Current Investments sank 200.05% in 2023, then jumped 893.33% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $34.8 million in 2021, then sank by 93.88% to $2.1 million in 2022, then surged by 140.09% to $5.1 million in 2023, then soared by 59.33% to $8.1 million in 2024, then sank by 49.57% to $4.1 million in 2025.
• The last three Cash & Current Investments figures came in at $4.1 million (Q4 2025), $1.7 million (Q3 2025), and $3.3 million (Q2 2025), per Business Quant data.